Ketorolac Tromethamine (ketorolac tromethamine)

No dosing information is available for this tab.

Ketorolac tromethamine is applied topically to the eye as an ophthalmic solution. To prevent contamination of the solution, patients should be instructed to avoid allowing the tip of the dispensing container to contact any surface, the eyelids, or surrounding structures. Contact lenses should be removed prior to administration of ketorolac tromethamine ophthalmic solution. The preservative-free solution is for single use only in one or both eyes; the preservative-free solution should be used immediately after opening and any unused portion should be discarded immediately after administration.

The manufacturer states that ketorolac tromethamine ophthalmic solution has been used safely in conjunction with other ophthalmic agents, including antibiotics, beta-adrenergic blocking agents, carbonic anhydrase inhibitors, cycloplegics, and/or mydriatics. The ophthalmic solution also has been used in conjunction with injectable sedatives (e.g., diazepam, hydroxyzine, lorazepam, promethazine hydrochloride), hyaluronidase, and/or local anesthetics (bupivacaine hydrochloride, lidocaine hydrochloride, tetracaine hydrochloride).

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

• Corneal degeneration
• Corneal erosion
• Diabetes mellitus
• Dry eye
• Hemophilia
• Increased risk of bleeding due to coagulation disorder
• Rheumatoid arthritis

There is no enhanced messaging for this drug.

Less Frequent

• Keratitis

Rare or Very Rare

• Asthma exacerbation
• Bronchospastic pulmonary disease
• Corneal erosion
• Corneal ulcer
• Impaired wound healing
• Ocular hemorrhage
• Perforation of cornea

More Frequent

• Blurred vision
• Conjunctival hemorrhage
• Conjunctival hyperemia
• Headache disorder
• Infiltrate of cornea
• Ocular hypertension
• Ocular pain

Less Frequent

• Contact dermatitis
• Ocular irritation
• Ocular itching
• Ocular redness
• Skin rash

Rare or Very Rare

• Corneal dystrophy
• Corneal edema
• Dry eye
• Eyelid edema
• Iritis

No enhanced messaging available.

No enhanced messaging available.

Reproduction studies in rabbits and rats receiving oral ketorolac tromethamine dosages up to 109 and 303 times the maximum recommended human topical ophthalmic dosage of ketorolac tromethamine 0.5% (on a mg/kg basis), respectively, have not revealed evidence of harm to the fetus. However, oral dosages exceeding 45 times the maximum recommended human topical ophthalmic dosage of ketorolac tromethamine 0.5% (on a mg/kg basis) in rats produced dystocia and was associated with an increased neonatal death rate. There are no adequate and controlled studies to date using ophthalmic ketorolac tromethamine in pregnant women, and the drug should be used during pregnancy only when the potential benefits justify the possible risk to the fetus. Ketorolac tromethamine ophthalmic solution should not be used during late pregnancy, since inhibitors of prostaglandin synthesis may have adverse effects on the fetal cardiovascular system (e.g., premature closure of the ductus arteriosus).

Because ketorolac is distributed into milk following systemic administration (see Pharmacokinetics: Distribution, in Ketorolac 28:08.04.92), the ophthalmic solution should be used with caution in nursing women.

No enhanced messaging available.